News The First Proof-of-Mechanism in a Randomized, Placebo-controlled Study in Targeted Protein Degradation 7/6/21 Read more Marking Kymera’s 5-Year Anniversary 6/7/21 Read more Becoming CEO: The First 18 Months 12/1/20 Read more IRAKIMiDs: A Single Small Molecule Approach to Developing Dual-Function Degraders for B Cell Lymphoma with Multiple Drivers 6/24/20 Read more Kymera’s IRAK4 degrader for hidradenitis suppurativa: Hitting an elusive target hard for a hard-to-treat inflammatory disease 2/18/20 Read more Targeted Protein Degradation Comes of Age (As Featured in LifeSciVC) 5/15/19 Read more Protein Degradation: New Rules for Drug Discovery 4/11/19 Read more Going after the “undruggable”: the STAT3 story 4/11/19 Read more
